TY  - JOUR
AU  - Albers, Peter
AU  - Krilaviciute, Agne
AU  - Seibold, Petra
AU  - de Vrieze, Maxime
AU  - Lakes, Jale
AU  - Kuczyk, Markus A
AU  - Harke, Nina N
AU  - Debus, Jürgen
AU  - Grott, Christoph A
AU  - Gschwend, Jürgen E
AU  - Herkommer, Kathleen
AU  - Soehne, Victoria A
AU  - Benner, Axel
AU  - Kristiansen, Glen
AU  - Hadaschik, Boris
AU  - Arsov, Christian
AU  - Antoch, Gerald
AU  - Schimmöller, Lars
AU  - Giesel, Frederik L
AU  - Makowski, Marcus R
AU  - Wacker, Frank
AU  - Schlemmer, Heinz-Peter
AU  - Kaaks, Rudolf
AU  - Becker, Nikolaus
TI  - Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial.
JO  - European urology oncology
VL  - nn
SN  - 2588-9311
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2025-01430
SP  - nn
PY  - 2025
N1  - #EA:C130#LA:C130# / epub
AB  - In general, low-risk and favorable intermediate-risk prostate cancers (PCs; International Society of Urological Pathology grade group [GG] 1 and GG 2) are slow-growing cancers with low metastatic potential. Active surveillance is recommended for GG 1 PC and can be recommended for GG 2 PC in the absence of adverse pathological parameters. Therefore, the question arises as to when low-grade PC should be detected in a screening setting. We conducted an analysis of the group with intermediate prostate-specific antigen (PSA) risk (1.5-2.99 ng/ml) from the PROBASE screening trial for young men (starting age 45 yr) and evaluated 159 biopsies performed for confirmed PSA ≥3 ng/ml in the first two biennial screening rounds. Of these biopsies, 37
KW  - Grade group (Other)
KW  - Intermediate risk (Other)
KW  - International Society of Urological Pathology (Other)
KW  - Prostate cancer (Other)
KW  - Screening (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40640052
DO  - DOI:10.1016/j.euo.2025.06.007
UR  - https://inrepo02.dkfz.de/record/302890
ER  -